Compare MPLX LP (MPLX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Novartis AG — how do they compare? MPLX LP trades at $56.75 (market cap $57.97B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 5× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.
| MPLX | NVS | |
|---|---|---|
Market Cap | $57.97B | $290.25B |
Sector | Technology | Health |
52-Week High | $59.17 | $168.62 |
52-Week Low | $47.80 | $113.50 |
Enterprise Value | $82.60B | $330.27B |
Dividend Yield | 7.54% | 3.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
